Patients & Caregivers

Breaking Boundaries Engineering The Future of Targeted Medicines

Our goal is to develop and provide safe, effective and life-improving medicines to people living with cancer and immune-inflammatory diseases.

Our lead oncology candidate ofra-vec (ofranergene obadenovec, or VB-111) is currently being studied in the following indications:

Ovarian Cancer

The OVAL Study is an ongoing Phase 3 registration-enabling clinical trial (NCT03398655) in women with recurrent platinum-resistant ovarian cancer. The trial is being conducted in collaboration with the GOG Foundation, Inc. Together, we strive to evolve the treatment paradigm in ovarian cancer, to help those living with the disease who do not respond to current therapies and whose cancer progresses despite treatment.


Phase 2 Trial of ofra-vec in Surgically Accessible Recurrent/Progressive GBM

Colorectal Cancer

Phase 2 Trial of ofra-vec in Combination with Nivolumab in People with Metastatic Colorectal Cancer (mCRC)